Straits Times Index
3,299.01 +6.32 (+0.19%) Nikkei
38,249.93 -24.12 (-0.06%) Hang Seng
18,150.04 +387.01 (+2.18%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,421.87 -2,833.54 (-4.70%) CMC Crypto 200
1,261.43 -77.64 (-5.80%)
Novartis AG (NVS)
After hours:
| Previous close | 97.13 |
| Open | 96.97 |
| Bid | 97.74 x 800 |
| Ask | 100.70 x 3100 |
| Day's range | 96.71 - 97.87 |
| 52-week range | 92.19 - 108.78 |
| Volume | |
| Avg. volume | 1,610,775 |
| Market cap | 198.94B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 22.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.78 (3.87%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem
- GlobeNewswire
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra
- GlobeNewswire
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto (+36% cc), Cosentyx (+25% cc), Kesimpta (+66% cc), Kisqali (+54% cc), Pluvicto (+47% cc) and Leqvio (+139% cc)Core operating income margin 38.4%, +340 basis points (cc), mainly driven by higher net salesOperating income grew +39% (cc, +29% USD) and net income grew +37% (cc, +25% USD), mainly driven
